Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Free Cash Flow (2016 - 2025)

Cytokinetics (CYTK) has disclosed Free Cash Flow for 16 consecutive years, with -$179.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Free Cash Flow changed N/A to -$179.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$312.8 million, a N/A change, with the full-year FY2025 number at -$512.7 million, down 28.41% from a year prior.
  • Free Cash Flow was -$179.7 million for Q4 2025 at Cytokinetics, down from -$133.1 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$28.6 million in Q1 2022 to a low of -$179.7 million in Q4 2025.
  • A 5-year average of -$92.0 million and a median of -$96.4 million in 2023 define the central range for Free Cash Flow.
  • Peak YoY movement for Free Cash Flow: crashed 714.29% in 2021, then soared 31.16% in 2023.
  • Cytokinetics' Free Cash Flow stood at -$62.5 million in 2021, then plummeted by 72.28% to -$107.7 million in 2022, then soared by 31.16% to -$74.1 million in 2023, then tumbled by 40.39% to -$104.0 million in 2024, then tumbled by 72.73% to -$179.7 million in 2025.
  • Per Business Quant, the three most recent readings for CYTK's Free Cash Flow are -$179.7 million (Q4 2025), -$133.1 million (Q1 2025), and -$104.0 million (Q3 2024).